Isogenica Discovery on Target PDF Poster
Isogenica is excited to announce its attendance at Discovery on Target 2021 September 27-30th
Isogenica’s Associate Director of Antibody Alliances, Marion Cubitt, will be attending Discovery on Target 2021 virtually on September 27-30th.
Marion will be presenting the latest Isogenica VHH data on ‘Synthetically-Derived PD-1 Antagonising VHHs Bind in Monomer and Multimer Formats to PD-L1-Expressing Breast Cancer Cells‘.
Do not miss out on the opportunity to have a live conversation with Marion at the
VIRTUAL POSTER CHAT (13:15 – 13:45 EDT, 29th Sept)
to discuss VHH applications in multiple formats such as bi-specifics and how you could apply Isogenica’s technology in your projects.
Further Information
Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
Contact
